139 related articles for article (PubMed ID: 20358440)
1. Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studies.
Hosmane B; Locke C; Chiu YL
J Biopharm Stat; 2010 May; 20(3):615-31. PubMed ID: 20358440
[TBL] [Abstract][Full Text] [Related]
2. Sample size and power estimation in "thorough" QT/QTc studies with parallel group design.
Hosmane B; Locke C; Chiu YL
J Biopharm Stat; 2010 May; 20(3):578-86. PubMed ID: 20358437
[TBL] [Abstract][Full Text] [Related]
3. Multiple comparisons of repeatedly measured response: issues of validation testing in thorough QT/QTc clinical trials.
Tsong Y; Yan LK; Zhong J; Nie L; Zhang J
J Biopharm Stat; 2010 May; 20(3):654-64. PubMed ID: 20358443
[TBL] [Abstract][Full Text] [Related]
4. Sample size calculations for crossover thorough QT studies: satisfaction of regulatory threshold and assay sensitivity.
Anand SP; Murray SC; Koch GG
J Biopharm Stat; 2010 May; 20(3):587-603. PubMed ID: 20358438
[TBL] [Abstract][Full Text] [Related]
5. Multiple comparisons of repeated measured response: issues of assessment of prolongation of QT interval in thorough QT trials.
Tsong Y; Zhong J
J Biopharm Stat; 2010 May; 20(3):604-14. PubMed ID: 20358439
[TBL] [Abstract][Full Text] [Related]
6. A comparison of several methods for analyzing data from thorough QT studies.
Tian H; Qiao W; Natarajan J
J Biopharm Stat; 2010 May; 20(3):632-40. PubMed ID: 20358441
[TBL] [Abstract][Full Text] [Related]
7. Statistical consideration in testing for assay sensitivity in a "thorough" QT study.
Sethuraman V; Wu S; Wang J
J Biopharm Stat; 2010 May; 20(3):641-53. PubMed ID: 20358442
[TBL] [Abstract][Full Text] [Related]
8. Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points.
Meng Z; Kringle R; Chen X; Zhao PL
J Biopharm Stat; 2010 May; 20(3):563-77. PubMed ID: 20358436
[TBL] [Abstract][Full Text] [Related]
9. Delayed effects in the exposure-response analysis of clinical QTc trials.
Glomb P; Ring A
J Biopharm Stat; 2012; 22(2):387-400. PubMed ID: 22251181
[TBL] [Abstract][Full Text] [Related]
10. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
[TBL] [Abstract][Full Text] [Related]
11. The joint modeling of drug and positive control effects to estimate sample size and power in crossover "thorough" QT/QTc studies.
Hosmane B; Locke C; Chiu YL
J Biopharm Stat; 2013; 23(4):871-80. PubMed ID: 23786591
[TBL] [Abstract][Full Text] [Related]
12. QT analysis: a complex answer to a 'simple' problem.
Li L; Desai M; Desta Z; Flockhart D
Stat Med; 2004 Sep; 23(17):2625-43. PubMed ID: 15316947
[TBL] [Abstract][Full Text] [Related]
13. Statistical characterization of QT prolongation.
Schall R; Ring A
J Biopharm Stat; 2010 May; 20(3):543-62. PubMed ID: 20358435
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian measurement error approach to QT interval correction and prolongation.
Chen J; Zhao X
J Biopharm Stat; 2010 May; 20(3):523-42. PubMed ID: 20358434
[TBL] [Abstract][Full Text] [Related]
15. Statistical characteristics of moxifloxacin-induced QTc effect.
Yan LK; Zhang J; Ng MJ; Dang Q
J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
[TBL] [Abstract][Full Text] [Related]
16. Use of the average baseline versus the time-matched baseline in parallel group thorough QT/QTc studies.
Meng Z; Quan H; Fan L; Kringle R; Sun G
J Biopharm Stat; 2010 May; 20(3):665-82. PubMed ID: 20358444
[TBL] [Abstract][Full Text] [Related]
17. A nonparametric approach to QT interval correction for heart rate.
Wang D; Cheung YB; Arezina R; Taubel J; Camm AJ
J Biopharm Stat; 2010 May; 20(3):508-22. PubMed ID: 20358433
[TBL] [Abstract][Full Text] [Related]
18. Further discussion on the design and analysis of thorough QTc clinical trials: guest editors' notes.
Tsong Y; Zhang J
J Biopharm Stat; 2010 May; 20(3):493-6. PubMed ID: 20358431
[No Abstract] [Full Text] [Related]
19. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
20. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
Cheng B; Chow SC; Burt D; Cosmatos D
J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]